Pomalidomide

featured

WARNING: This product is for research use only, not for human or veterinary use.

Description:Pomalidomide, also known as CC4047, is an orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). Pomalidomide was approved on February 8, 2013 as a treatment for relapsed and refractory multiple myeloma.

Price and Availability

Pomalidomide, purity > 98%, is in stock. The same day shipping out after order is received.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 202310Name: PomalidomideCAS#: 19171-19-8Chemical Formula: C13H11N3O4Exact Mass: 273.07496Molecular Weight: 273.24Elemental Analysis:C, 57.14; H, 4.06; N, 15.38; O, 23.42

Synonym:CC4047; CC 4047; CC-4047; Pomalidomide. Brand name: Pomalyst.

IUPAC/Chemical Name:4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

InChi Key:UVSMNLNDYGZFPF-UHFFFAOYSA-N

InChi Code:InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)

SMILES Code:O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC=C3N)=O

Technical Data

References

1: Elkinson S, McCormack PL. Pomalidomide: FirstGlobal Approval. Drugs. 2013 Apr 10. [Epub ahead of print] PubMed PMID:23572409.

2: Traynor K. Pomalidomide approved for multiple myeloma. Am J HealthSyst Pharm. 2013 Mar 15;70(6):474. doi: 10.2146/news130020. PubMed PMID:23456394.

3: Henry JY, Labarthe MC, Meyer B, Dasgupta P, Dalgleish AG, GalustianC. Enhanced cross-priming of naive CD8+ T cells by DCs treated by theIMiDs(®) immunomodulatory compounds Lenalidomide and Pomalidomide.Immunology. 2013 Feb 1. doi: 10.1111/imm.12087. [Epub ahead of print]PubMed PMID: 23374145.

4: Ellis PM, Jungnelius U, Zhang J, Fandi A, Beck R, Shepherd FA. APhase I Study of Pomalidomide (CC-4047) in Combination with Cisplatinand Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer. JThorac Oncol. 2013 Apr;8(4):423-8. doi: 10.1097/JTO.0b013e318282707b.PubMed PMID: 23370364.

5: Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, Mathiot C,Petillon MO, Macro M, Roussel M, Pegourie B, Kolb B, Stoppa AM, HennacheB, Bréchignac S, Meuleman N, Thielemans B, Garderet L, Royer B, Hulin C,Benboubker L, Decaux O, Escoffre-Barbe M, Michallet M, Caillot D,Fermand JP, Avet-Loiseau H, Facon T; Intergroupe Francophone du Myélome.Pomalidomide plus low-dose dexamethasone is active and well tolerated inbortezomib and lenalidomide-refractory multiple myeloma: IntergroupeFrancophone du Myelome 2009-02. Blood. 2013 Mar 14;121(11):1968-75. doi:10.1182/blood-2012-09-452375. Epub 2013 Jan 14. PubMed PMID: 23319574.

6: Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J,Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N,McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M,Zaki MH, Jacques C, Anderson KC. Phase 1 study of pomalidomide MTD,safety, and efficacy in patients with refractory multiple myeloma whohave received lenalidomide and bortezomib. Blood. 2013 Mar14;121(11):1961-7. doi: 10.1182/blood-2012-08-450742. Epub 2012 Dec 14.PubMed PMID: 23243282.

7: Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, Capone L, PartonA, Kim-Kang H, Surapaneni S, Kumar G. Absorption, metabolism andexcretion of [14C]pomalidomide in humans following oral administration.Cancer Chemother Pharmacol. 2013 Feb;71(2):489-501. doi:10.1007/s00280-012-2040-6. Epub 2012 Dec 1. PubMed PMID: 23203815;PubMed Central PMCID: PMC3556473.

8: Bolzoni M, Storti P, Bonomini S, Todoerti K, Guasco D, Toscani D,Agnelli L, Neri A, Rizzoli V, Giuliani N. Immunomodulatory drugslenalidomide and pomalidomide inhibit multiple myeloma-inducedosteoclast formation and the RANKL/OPG ratio in the myelomamicroenvironment targeting the expression of adhesion molecules. ExpHematol. 2012 Nov 23. doi:pii: S0301-472X(12)00542-5.10.1016/j.exphem.2012.11.005. [Epub ahead of print] PubMed PMID:23178378.

9: Ruchelman AL, Man HW, Zhang W, Chen R, Capone L, Kang J, Parton A,Corral L, Schafer PH, Babusis D, Moghaddam MF, Tang Y, Shirley MA,Muller GW. Isosteric analogs of lenalidomide and pomalidomide: synthesisand biological activity. Bioorg Med Chem Lett. 2013 Jan 1;23(1):360-5.doi: 10.1016/j.bmcl.2012.10.071. Epub 2012 Oct 27. PubMed PMID:23168019.

10: Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action ofimmune-modulatory drugs thalidomide, lenalidomide and pomalidomide inmultiple myeloma. Leuk Lymphoma. 2013 Apr;54(4):683-7. doi:10.3109/10428194.2012.728597. Epub 2012 Sep 28. PubMed PMID: 22966948.

MedKoo，由化学家和药学家陈清奇博士。北卡罗莱纳州的研究三角区（ResearchTrianglePark,简称RTP)，是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司，该公司的业务范围主要是为全球所有从事抗癌药物研究和开发的制药公司，高校，研究院所，政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。

中文名MedKoo中    文美帝药库医药科技公司创立于2008年总部位于美国东海岸

MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务。

MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务和分子有竞争力的价格。MedKoo是您可靠的合作伙伴采购药物发现和药物分子。

MedKoo是世界的抗癌化学试剂和激酶抑制剂供应商之一。我们制造，销售和分销用于肿瘤学研究的高质量抗癌小分子试剂。我们的使命是建立世界上全面的抗癌小分子集合。我们还为制药行业，医学研究组织和学术机构提供高质量的研究服务。我们致力于以具有竞争力的价格提供服务和分子。MedKoo是您可靠的药物发现和药物分子采购合作伙伴。

CRISPR-Cas9是近年兴起的用于靶向基因组特定位置，进行DNA修饰的重要工具。研究发现CRISPR是细菌为了应对病毒的攻击而演化而来的获得性免疫防御机制。具体来说，在CRISPR和Cas9的作用下，经由小RNA分子的引导，靶向并沉默入侵者遗传物质核酸的关键部分。在该系统中，crRNA（CRISPR-derivedRNA）与tracrRNA（trans-activatingRNA）结合形成的复合物能特异性识别靶基因序列，并引导Cas9核酸内切酶在靶定位点剪切双链DNA，随后，细胞的非同源末端连接修复机制（NHEJ）重新连接断裂处的基因组DNA，并引入插入或缺失突变。另外也可以提供一个外源双链供体DNA（Donor）通过同源重组（HR）整合进断裂处的基因组，从而达到对基因组DNA进行修饰的目的。
目前，CRISPR-Cas9系统的高效基因组编辑功能已被应用于多种生物，包括小鼠、大鼠、斑马鱼、秀丽隐杆线虫，也包含多种细菌和植物，甚至在人体上也有应用。